Intelliseq
Genomic bioinformatics · Clinical genomics
Overview
Bioinformatics startup turning raw sequencing data into clinical-grade genomic reports — pipelines and apps for diagnostic labs.
What they do
Intelliseq is a Krakow-based clinical-genomics bioinformatics company, founded in 2014 by a team from Jagiellonian University. It automates the analysis and interpretation of human genome sequence data, turning raw reads into clinical-grade reports. Its platform (referred to as Intelliseq FLOW / iFlow) provides cloud-based, automated pipelines covering hereditary disorders, somatic tumors, pharmacogenomics and polygenic risk scores, aimed at diagnostic laboratories and research institutions.
Lead program & status
The lead product is the iFlow/FLOW genome-interpretation engine, which ingests sequencing data and outputs structured clinical reports. In March 2025 Intelliseq raised about €4.5M in a round led by Vinci HiTech (Vinci S.A.), with participation from Unfold.vc and private investors including Tadeusz Wesolowski; the capital is earmarked for US expansion and for developing disease-risk-prediction algorithms. The company has reported partnerships with the US Metrodora Institute and with DNAnexus, the platform underpinning large genomic biobanks such as UK Biobank.
Why it matters
Sequencing is now cheap; interpretation is the bottleneck. Intelliseq targets that gap with automated, reproducible pipelines that let labs scale genetic diagnostics without building bioinformatics teams from scratch, positioning it as infrastructure for clinical genomics.
FAQ
- What does Intelliseq's platform do?
- Its iFlow/FLOW platform runs automated, cloud-based pipelines that take raw sequencing data and produce clinical-grade genomic reports across areas like hereditary disease, somatic cancer, pharmacogenomics and polygenic risk scores.
- Who is Intelliseq for?
- Mainly diagnostic laboratories and research institutions that need to interpret genomic data at scale without building their own bioinformatics infrastructure.
- How much has Intelliseq raised recently?
- In March 2025 it secured about €4.5M led by Vinci HiTech, with Unfold.vc and private investors participating, to fund US expansion and risk-prediction algorithm development.
Technology
Intelliseq works in AI-Driven Drug Discovery — Compressing years of trial-and-error chemistry into months of computation.
Read the AI-Driven Drug Discovery brief →Related companies
Company website / source ↗ Open the interactive map →
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.